RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. The company offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a tre… Read more
RaySearch Laboratories AB (publ) (RSLBF) - Net Assets
Latest net assets as of September 2025: $919.30 Million USD
Based on the latest financial reports, RaySearch Laboratories AB (publ) (RSLBF) has net assets worth $919.30 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.94 Billion) and total liabilities ($1.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $919.30 Million |
| % of Total Assets | 47.28% |
| Annual Growth Rate | 19.77% |
| 5-Year Change | 26.26% |
| 10-Year Change | 174.39% |
| Growth Volatility | 33.53 |
RaySearch Laboratories AB (publ) - Net Assets Trend (2003–2024)
This chart illustrates how RaySearch Laboratories AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RaySearch Laboratories AB (publ) (2003–2024)
The table below shows the annual net assets of RaySearch Laboratories AB (publ) from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $876.71 Million | +19.24% |
| 2023-12-31 | $735.23 Million | +11.88% |
| 2022-12-31 | $657.16 Million | +4.59% |
| 2021-12-31 | $628.31 Million | -9.51% |
| 2020-12-31 | $694.35 Million | -1.58% |
| 2019-12-31 | $705.47 Million | +7.30% |
| 2018-12-31 | $657.45 Million | +13.27% |
| 2017-12-31 | $580.42 Million | +26.13% |
| 2016-12-31 | $460.19 Million | +44.03% |
| 2015-12-31 | $319.52 Million | +27.02% |
| 2014-12-31 | $251.55 Million | +27.95% |
| 2013-12-31 | $196.60 Million | -9.63% |
| 2012-12-31 | $217.55 Million | +10.60% |
| 2011-12-31 | $196.70 Million | -0.03% |
| 2010-12-31 | $196.76 Million | +6.44% |
| 2009-12-31 | $184.86 Million | +22.88% |
| 2008-12-31 | $150.44 Million | +9.13% |
| 2007-12-31 | $137.85 Million | +16.75% |
| 2006-12-31 | $118.07 Million | +44.25% |
| 2005-12-31 | $81.85 Million | +150.13% |
| 2004-12-31 | $32.72 Million | +65.10% |
| 2003-12-31 | $19.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RaySearch Laboratories AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 86195200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $856.93 Million | 97.74% |
| Common Stock | $17.14 Million | 1.96% |
| Other Comprehensive Income | $662.00K | 0.08% |
| Other Components | $1.98 Million | 0.23% |
| Total Equity | $876.71 Million | 100.00% |
RaySearch Laboratories AB (publ) Competitors by Market Cap
The table below lists competitors of RaySearch Laboratories AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TRUWORTHS INTL RC-00015
F:IUE
|
$634.97 Million |
|
EMTEK (Shenzhen) Co. Ltd.
SHE:300938
|
$634.98 Million |
|
Chongqing Gas Grp Corp Ltd
SHG:600917
|
$635.06 Million |
|
TeamViewer SE
LSE:0A36
|
$635.43 Million |
|
Nanjing Xinlian Electronics Co Ltd
SHE:002546
|
$634.85 Million |
|
Elmos Semiconductor SE
PINK:ELTTF
|
$634.53 Million |
|
Vardhman Textiles Limited
NSE:VTL
|
$634.50 Million |
|
No Va Land Investment Group Corp
VN:NVL
|
$634.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RaySearch Laboratories AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 735,232,000 to 876,707,000, a change of 141,475,000 (19.2%).
- Net income of 203,513,000 contributed positively to equity growth.
- Dividend payments of 68,566,000 reduced retained earnings.
- Other comprehensive income increased equity by 6,527,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $203.51 Million | +23.21% |
| Dividends Paid | $68.57 Million | -7.82% |
| Other Comprehensive Income | $6.53 Million | +0.74% |
| Other Changes | $1.00 | +0.0% |
| Total Change | $- | 19.24% |
Book Value vs Market Value Analysis
This analysis compares RaySearch Laboratories AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 38.92x to 0.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.58 | $22.50 | x |
| 2004-12-31 | $0.95 | $22.50 | x |
| 2005-12-31 | $2.39 | $22.50 | x |
| 2006-12-31 | $3.43 | $22.50 | x |
| 2007-12-31 | $4.00 | $22.50 | x |
| 2008-12-31 | $4.39 | $22.50 | x |
| 2009-12-31 | $5.39 | $22.50 | x |
| 2010-12-31 | $5.74 | $22.50 | x |
| 2011-12-31 | $5.74 | $22.50 | x |
| 2012-12-31 | $6.40 | $22.50 | x |
| 2013-12-31 | $5.77 | $22.50 | x |
| 2014-12-31 | $7.34 | $22.50 | x |
| 2015-12-31 | $9.32 | $22.50 | x |
| 2016-12-31 | $13.42 | $22.50 | x |
| 2017-12-31 | $16.93 | $22.50 | x |
| 2018-12-31 | $19.18 | $22.50 | x |
| 2019-12-31 | $20.58 | $22.50 | x |
| 2020-12-31 | $20.25 | $22.50 | x |
| 2021-12-31 | $18.33 | $22.50 | x |
| 2022-12-31 | $19.17 | $22.50 | x |
| 2023-12-31 | $21.45 | $22.50 | x |
| 2024-12-31 | $25.59 | $22.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RaySearch Laboratories AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.21%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.07%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.39x
- Recent ROE (23.21%) is above the historical average (13.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -25.34% | -22.68% | 0.72x | 1.55x | $-7.01 Million |
| 2004 | 39.43% | 32.68% | 0.87x | 1.39x | $9.63 Million |
| 2005 | 35.60% | 41.72% | 0.65x | 1.31x | $20.96 Million |
| 2006 | 30.68% | 52.51% | 0.47x | 1.24x | $24.41 Million |
| 2007 | 14.35% | 30.57% | 0.37x | 1.26x | $5.99 Million |
| 2008 | 12.11% | 29.07% | 0.33x | 1.25x | $3.18 Million |
| 2009 | 16.31% | 36.02% | 0.36x | 1.26x | $11.66 Million |
| 2010 | 14.69% | 24.54% | 0.46x | 1.30x | $9.22 Million |
| 2011 | 8.65% | 13.49% | 0.48x | 1.33x | $-2.66 Million |
| 2012 | 9.13% | 10.91% | 0.62x | 1.35x | $-1.89 Million |
| 2013 | -10.60% | -10.19% | 0.68x | 1.52x | $-40.50 Million |
| 2014 | 23.79% | 20.98% | 0.73x | 1.55x | $34.68 Million |
| 2015 | 21.97% | 17.66% | 0.82x | 1.52x | $38.26 Million |
| 2016 | 32.90% | 28.49% | 0.74x | 1.56x | $105.39 Million |
| 2017 | 20.27% | 20.10% | 0.64x | 1.58x | $59.58 Million |
| 2018 | 11.94% | 12.52% | 0.57x | 1.68x | $12.78 Million |
| 2019 | 7.15% | 6.80% | 0.59x | 1.79x | $-20.14 Million |
| 2020 | -1.31% | -1.39% | 0.51x | 1.85x | $-78.52 Million |
| 2021 | -7.53% | -7.37% | 0.37x | 2.78x | $-110.15 Million |
| 2022 | 3.62% | 2.82% | 0.45x | 2.85x | $-41.94 Million |
| 2023 | 11.09% | 7.98% | 0.52x | 2.66x | $8.05 Million |
| 2024 | 23.21% | 17.07% | 0.57x | 2.39x | $115.84 Million |
Industry Comparison
This section compares RaySearch Laboratories AB (publ)'s net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RaySearch Laboratories AB (publ) (RSLBF) | $919.30 Million | -25.34% | 1.11x | $634.88 Million |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |